Last reviewed · How we verify
Psigodal (MEPIPRAZOLE)
Psigodal (generic name: MEPIPRAZOLE) is a drug. It is currently in Phase 2 development.
Mepiprazole is thought to work by modulating neurotransmitter activity in the brain.
Mepiprazole, also known as Psigodal, is a small molecule drug with unknown target and drug class. It is currently owned by an unspecified company, and its commercial status is unclear. Mepiprazole is used to treat unspecified indications, but its FDA approval status is unknown. The drug's pharmacokinetic properties, including half-life and bioavailability, are also unknown. Further research is needed to fully understand the safety and efficacy of mepiprazole.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MEPIPRAZOLE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is a busy city with many different streets and intersections. Mepiprazole helps to regulate the flow of traffic by adjusting the signals that control the movement of neurotransmitters, which are like the cars on the road. This can help to improve communication between different parts of the brain and alleviate symptoms of certain conditions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Psigodal CI brief — competitive landscape report
- Psigodal updates RSS · CI watch RSS
Frequently asked questions about Psigodal
What is Psigodal?
How does Psigodal work?
What is the generic name of Psigodal?
What development phase is Psigodal in?
Related
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing